|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
gptkb:nivolumab
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2011
|
|
gptkbp:ATCCode
|
L01XC11
|
|
gptkbp:brand
|
gptkb:Yervoy
|
|
gptkbp:CASNumber
|
477202-00-9
|
|
gptkbp:combinationTherapy
|
yes
|
|
gptkbp:contraindication
|
severe immune-mediated reactions
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:eliminatedIn
|
not renally excreted
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:halfLife
|
15.4 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ipilimumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
gptkb:microsatellite_instability-high_colorectal_cancer
gptkb:unresectable_malignant_pleural_mesothelioma
gptkb:advanced_renal_cell_carcinoma
metastatic melanoma
adjuvant treatment of melanoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IgG1_kappa
|
|
gptkbp:mechanismOfAction
|
CTLA-4 inhibitor
|
|
gptkbp:metabolism
|
proteolytic enzymes
|
|
gptkbp:monotherapy
|
yes
|
|
gptkbp:origin
|
fully human antibody
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
immune-related adverse events
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
pruritus
hepatitis
rash
inflammatory bowel disease
pneumonitis
hypophysitis
|
|
gptkbp:target
|
gptkb:CTLA-4
|
|
gptkbp:UNII
|
83HN0GTJ6D
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
colorectal cancer
melanoma
hepatocellular carcinoma
renal cell carcinoma
malignant pleural mesothelioma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CTLA-4
|
|
gptkbp:bfsLayer
|
6
|